Clinical Trial Update: Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the diagnostic utility of rhPSMA-7.3 (18F) PET/CT for men with prostate cancer on active surveillance; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• rhPSMA-7.3 (18F) PET/CT

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Prostatic Neoplasms, Prostate Cancer | Phase 2 | Status: RECRUITING